In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
WCK 771 demonstrated MIC(50) and MIC(90)s of 0.03 and 1 microg/ml, respectively, against 297 recent U.S. community-acquired and hospital strains of Staphylococcus aureus, irrespective of quinolone or glycopeptide resistance. Against quinolone-resistant strains, MIC(90)s of WCK 771 and moxifloxacin were 1 and 16 microg/ml, respectively.
Bhagwat
Sachin S
SS
Wockhardt Research Center, Aurangabad, India.
McGhee
Pamela
P
Kosowska-Shick
Klaudia
K
Patel
Mahesh V
MV
Appelbaum
Peter C
PC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology*; D024881:Drug Resistance, Bacterial / Q000187:drug effects*; D024841:Fluoroquinolones / Q000494:pharmacology*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014481:United States / Q000453:epidemiology; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D015363:Quinolones; C490933:WCK 771